Peptide Fragments for Diabetes Treatment via Beta-Cell Stimulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes, particularly type 1 and type 2, face challenges such as weight gain, increased cancer risk, and hypoglycemia, necessitating the development of novel non-insulin compounds that can address insulin resistance and hyperglycemia while reducing associated complications.
Innovation Solution
Development of specific peptides, such as those with amino acid sequences like X1LX2YGIK and Z1Z2SZ3Z4YGLR, which stimulate β-cell proliferation, protect against apoptosis, and enhance insulin secretion, thereby lowering plasma glucose levels and delaying the onset of diabetes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If insulin treatment is used to treat diabetes, then blood glucose levels are controlled, but weight gain and increased risks of cancer and hypoglycemia occur
Solution Approach 1:
The patent uses peptide compounds (specifically GLP-1 receptor agonists and related peptides) as intermediary substances that indirectly regulate blood glucose through stimulating endogenous insulin secretion and improving insulin sensitivity, rather than directly administering insulin. This mediator approach achieves glucose control while avoiding the direct harmful effects of exogenous insulin treatment
Solution Approach 2:
The invention modifies the chemical structure parameters of known active peptides by creating analogues with altered amino acid sequences, thereby changing their pharmacological properties to achieve better glucose control with reduced side effects. The systematic variation of peptide structures allows optimization of therapeutic efficacy while minimizing adverse effects
2Reliability
If long-acting GLP-1 receptor agonists are used to complement insulin treatment, then insulin sensitivity increases and glucagon secretion decreases, but the complexity of treatment regimen increases
Solution Approach 1:
The patent develops peptide compounds that perform multiple therapeutic functions simultaneously: stimulating insulin secretion, improving insulin sensitivity, suppressing glucagon secretion, and protecting beta cells. This multi-functional approach consolidates what would otherwise require multiple separate medications into a single therapeutic agent, reducing treatment complexity
3Object-affected harmful factors
If novel non-insulin compounds are developed to treat diabetes, then associated complications such as weight gain and cancer risk may be reduced, but the reliability of glucose metabolism control must be maintained
Solution Approach 1:
The patent replaces the direct mechanical action of exogenous insulin (which binds to insulin receptors and forces glucose uptake) with a biochemical signaling system. The peptide compounds activate endogenous insulin secretion through GLP-1 receptor signaling, creating a more physiological and regulated glucose control mechanism that avoids the pathological effects of high-dose exogenous insulin while maintaining effective glucose metabolism control
Data Source
AI summary
The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptide fragments.